Frontiers in Oncology (Jun 2022)

Heterogeneity Analysis of Bladder Cancer Based on DNA Methylation Molecular Profiling

  • Shuyu Wang,
  • Dali Xu,
  • Bo Gao,
  • Shuhan Yan,
  • Yiwei Sun,
  • Xinxing Tang,
  • Yanjia Jiao,
  • Shan Huang,
  • Shumei Zhang

DOI
https://doi.org/10.3389/fonc.2022.915542
Journal volume & issue
Vol. 12

Abstract

Read online

Bladder cancer is a highly complex and heterogeneous malignancy. Tumor heterogeneity is a barrier to effective diagnosis and treatment of bladder cancer. Human carcinogenesis is closely related to abnormal gene expression, and DNA methylation is an important regulatory factor of gene expression. Therefore, it is of great significance for bladder cancer research to characterize tumor heterogeneity by integrating genetic and epigenetic characteristics. This study explored specific molecular subtypes based on DNA methylation status and identified subtype-specific characteristics using patient samples from the TCGA database with DNA methylation and gene expression were measured simultaneously. The results were validated using an independent cohort from GEO database. Four DNA methylation molecular subtypes of bladder cancer were obtained with different prognostic states. In addition, subtype-specific DNA methylation markers were identified using an information entropy-based algorithm to represent the unique molecular characteristics of the subtype and verified in the test set. The results of this study can provide an important reference for clinicians to make treatment decisions.

Keywords